Novo Nordisk says Victoza helps lower heart risks
Copenhagen: Novo Nordisk said on Friday the results from a trial showed that its Victoza diabetes drug significantly reduced the risks of major adverse cardiovascular events."People with type 2 diabetes generally have a higher risk of experiencing major adverse cardiovascular events. That's why we are very excited about the results from LEADER (trial), which showed that Victoza ... also...
Login or Register to read the full article
Copenhagen: Novo Nordisk said on Friday the results from a trial showed that its Victoza diabetes drug significantly reduced the risks of major adverse cardiovascular events.
"People with type 2 diabetes generally have a higher risk of experiencing major adverse cardiovascular events. That's why we are very excited about the results from LEADER (trial), which showed that Victoza ... also reduces their risk of major adverse cardiovascular events," Novo's Chief Science Officer Mads Krogsgaard Thomsen said.
Novo Nordisk's shares jumped as much as 7 percent in the minutes after the announcement.
"People with type 2 diabetes generally have a higher risk of experiencing major adverse cardiovascular events. That's why we are very excited about the results from LEADER (trial), which showed that Victoza ... also reduces their risk of major adverse cardiovascular events," Novo's Chief Science Officer Mads Krogsgaard Thomsen said.
Novo Nordisk's shares jumped as much as 7 percent in the minutes after the announcement.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd